Exploring PrP <sup>C</sup> unfolding as a critical step preceding its refolding in the context of PrP <sup>Sc</sup> propagation
Abstract
It might have been believed that elucidation of the atomistic structure of PrP Sc would lead to an immediate understanding of the mechanism of prion propagation. However, PrP Sc , now known to be a “simple” amyloid, can only template a previously unfolded polypeptide chain. Therefore, PrP Sc can easily template the disordered ~90–120 domain of an incoming PrP C molecule, but not its ~121–231 folded domain (FD). The FD needs to accommodate into the ~121–230 PrP Sc surface, an inert “procrustean bed”. Thus, a mechanism for concerted unfolding/refolding of the FD must exist, with FD unfolding as a key element. To explore how this might happen, we performed thermal unfolding of recombinant bank vole PrP C (90–231), a universal PrP Sc propagator, tracking changes at the residue level with solution NMR to pinpoint early unfolding propensity. Our data suggest that a key early event is the destabilization of the short β1-β2 assembly and that the segment contiguous to the disordered tail, ~121–140, encompassing β1 and its adjacent coils, is the most likely region to unfold first. Spectroscopic data obtained at higher temperatures suggest that portions of alpha helix α2 are likely the last elements of the FD to unfold and refold into the PrP Sc conformation. Molecular Dynamics simulations assisted the interpretation of these changes and suggest separation of α1 from the rest of the FD ensemble. Our data provide a conceivable timeline of the early events in PrP Sc -assisted conversion of PrP C and should serve as a starting framework to develop a future atomistic model of PrP Sc propagation.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (13)
Sanaz Sabzehei
Center for Research in Molecular Medicine and Chronic Diseases and Department of Medical Sciences, University of Santiago de Compostela-Instituto de Investigación Sanitaria de Santiago
Marta Rigoli
Department of Cellular, Computational and Integrative Biology, University of Trento
Raúl Cacheiro
Center for Research in Molecular Medicine and Chronic Diseases and Department of Medical Sciences, University of Santiago de Compostela-Instituto de Investigación Sanitaria de Santiago
Iria Díaz-Arias
Center for Research in Molecular Medicine and Chronic Diseases and Department of Medical Sciences, University of Santiago de Compostela-Instituto de Investigación Sanitaria de Santiago
Hasier Eraña
Asociación Centro de Investigación Cooperativa en Biociencias, Basque Research and Technology Alliance, Prion Research Lab
Rubén P. Lago
Center for Research in Molecular Medicine and Chronic Diseases and Department of Medical Sciences, University of Santiago de Compostela-Instituto de Investigación Sanitaria de Santiago
Arcadio Guerra
Center for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela
Human Rezaei
Université Paris-Saclay, Institut National de Recherche pour l‘Agriculture, l‘Alimentation et l‘Environnement, Université Versailles-Saint Quentin, Unité de Virologie et d‘Immunologie Moléculaires
Joaquín Castilla
Asociación Centro de Investigación Cooperativa en Biociencias, Basque Research and Technology Alliance, Prion Research Lab
Emiliano Biasini
Department of Cellular, Computational and Integrative Biology, University of Trento
Víctor M. Sánchez-Pedregal
Department of Organic Chemistry, University of Santiago de Compostela
Manuel Martín-Pastor
Unidade de Resonancia Magnética, University of Santiago de Compostela
Jesús R. Requena
Center for Research in Molecular Medicine and Chronic Diseases and Department of Medical Sciences, University of Santiago de Compostela-Instituto de Investigación Sanitaria de Santiago